Novozymes downgrades following failing sales

Novozymes' US sales have not panned out, limiting the Danish enzyme producer's growth.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novozymes' US growth outlook dwindles
For subscribers
Novozymes CFO: Powerful momentum in bioenergy division
For subscribers
Novozymes' bioenergy division continues to grow
For subscribers